Jennifer Tatalovich, MD
Urogynecology and Reconstructive Pelvic Surgery · Franklin, TNNPI 1124226477
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 214 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,021 and has fallen 64.8% since, to $360 in 2025. That places this record below the midpoint for urogynecology and reconstructive pelvic surgery clinicians in TN, where the typical reported total is $5,304.
Across 214 payments — averaging $22.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$909
- Astellas Pharma US Inc$731
- AbbVie$708
- Axonics, Inc.$411
- Coloplast$379
- Caldera Medical, Inc$311
- plus $1K from 19 others
What the payments were for
- Food & beverage$4,74599%
- Education$531%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 35 | $909 |
| Astellas Pharma US Inc | 42 | $731 |
| AbbVie(2 entities) | 39 | $708 |
| Axonics, Inc. | 16 | $411 |
| Coloplast | 9 | $379 |
| Caldera Medical, Inc | 4 | $311 |
| Sumitomo Pharma America, Inc. | 13 | $299 |
| Therapeuticsmd, Inc. | 11 | $183 |
| Coopersurgical, Inc. | 6 | $126 |
| Urovant Sciences Inc | 6 | $115 |
| Millicent US Inc | 5 | $88 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $72 |
| Hologic Sales And Service, LLC | 2 | $59 |
| Laborie Medical Technologies Corp. | 4 | $56 |
| Medtronic | 3 | $54 |
| Ardelyx, Inc. | 2 | $47 |
| Minerva Surgical, Inc | 1 | $35 |
| Gynesonics, Inc. | 1 | $33 |
| Covidien LP | 2 | $29 |
| Pfizer | 1 | $29 |
| 180 Medical, Inc. | 2 | $28 |
| Olympus America Inc. | 2 | $27 |
| Ironwood Pharmaceuticals, Inc | 1 | $25 |
| Applied Medical Resources Corporation | 1 | $23 |
| Ambu Inc. | 2 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,799 in reported general payments places this provider in the 45th percentile of 24 urogynecology and reconstructive pelvic surgery providers in Tennessee.
See all urogynecology and reconstructive pelvic surgery providers in Tennessee →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 270 | $196,511 |
| Estradiol | 521 | $60,150 |
| MyrbetriqMirabegron | 39 | $23,466 |
| EstringEstradiol | 26 | $13,387 |
| Solifenacin Succinate | 142 | $11,293 |
| YuvafemEstradiol | 56 | $9,198 |
| PremarinEstrogens, Conjugated | 24 | $8,523 |
| Estradiol (Twice Weekly)Estradiol | 60 | $6,735 |
| Methenamine Hippurate | 42 | $5,335 |
| Trospium Chloride ErTrospium Chloride | 24 | $4,708 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 89 | $2,659 |
| Tolterodine Tartrate ErTolterodine Tartrate | 48 | $2,232 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 14 | $1,440 |
| Trospium Chloride | 14 | $1,381 |
| Fluconazole | 168 | $1,206 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $299 | $196,511270 claims |
| Astellas Pharma US IncMyrbetriq | $731 | $23,46639 claims |
| PfizerEstring, Premarin | $29 | $21,91150 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 24 urogynecology and reconstructive pelvic surgery providers in Tennessee.
Other urogynecology and reconstructive pelvic surgery in Franklin
- Barry JarnaginFranklin$57K
- Tara AllenNashville$100K
- C BowlingKnoxville$52K
- Rena AzarSouth Pittsburg$23K
- Marcy AbelNashville$22K
- Roland HuffakerJohnson City$17K
- Henry OkaforChattanooga$13K
- Carson KaeserChattanooga$10K
- Jeffrey McQuearyBristol$9K
- Val VogtGermantown$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.